Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study.

Satoshi YamasakiTakumi MatsushimaMariko MinamiMasanori KadowakiKen TakaseHiromi Iwasaki

Published in: European geriatric medicine (2021)

Strategies that carefully select elderly patients aged 80 years and older with DLBCL using CGA may help to identify individuals suitable for novel therapies.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
end stage renal disease
physical activity
ejection fraction
chronic kidney disease
newly diagnosed
middle aged
community dwelling